The math operators view organizes Price Series Summation operator and supporting indicators around Cognition Therapeutics and Seres Therapeutics. The analysis highlights relative price relationships between Cognition Therapeutics and Seres Therapeutics and frames technical signals with volatility and risk context.
The output start index for this execution was zero with a total number of output elements of sixty-one. Cognition Therapeutics Price Series Summation is a cross summation of Cognition Therapeutics price series and its benchmark/peer.
Cognition Therapeutics Technical Analysis Modules
Most technical analysis of Cognition Therapeutics help investors determine whether a current trend will continue and, if not, when it will shift. We provide a combination of tools to recognize potential entry and exit points for Cognition from various momentum indicators to cycle indicators. When you analyze Cognition charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Cognition Therapeutics, Inc. was incorporated in 2007 and is headquartered in Purchase, New York. Cognition Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 19 people. Downside history and drawdown behavior provide context for risk expectations in Cognition Therapeutics. Downside profile remains relatively contained. Cognition Therapeutics has a market cap of 98.87 M, ROE of -109.73%.
Methodology
Unless otherwise specified, financial data for Cognition Therapeutics is derived from periodic company reporting (annual and quarterly where available). Asset-level metrics are computed daily by Macroaxis LLC and refreshed regularly based on asset type. Cognition (USA Stocks:CGTX) prices are typically delayed by approximately 20 minutes from primary exchanges for listed equities. Data may be delayed depending on reporting sources and market conventions. Assumptions: The dataset for Cognition Therapeutics incorporates public filings and market reference sources and official institutional disclosures, including U.S. Securities and Exchange Commission (SEC) via EDGAR and the U.S. Patent & Trademark Office (USPTO). Some inputs may not update instantaneously. All analytics are generated using standardized, rules-based models designed to promote consistency and comparability across instruments. Model assumptions, reference parameters, and selected computational inputs are available in the Model Inputs section. If you have questions about our data sources or methodology, please contact Macroaxis Support.
Analyst Sources
Cognition Therapeutics may have analyst coverage included in Macroaxis-derived consensus inputs when available. Updates may occur throughout the day.
Tracking Cognition Therapeutics inside a portfolio is useful because individual winners can still weaken diversification or distort overall risk targets. A disciplined tracking process turns performance data into better decisions instead of more noise.
Generate Optimal Portfolios
Align your risk and return expectations
By capturing risk tolerance and investment horizon, Macroaxis optimization evaluates acceptable risk for target return profiles. The process summarizes how much risk can be taken for a given return goal.
A structured review of Cognition Therapeutics often starts with core financial statements and trend context. Key ratios help frame profitability, efficiency, and growth context for Cognition Therapeutics Stock. Highlighted below are reports that provide context for Cognition Therapeutics Stock:
Cognition Therapeutics has a market cap of 98.87 M, ROE of -109.73%. Trending Equities can help frame allocation decisions. The allocation includes a position in Cognition Therapeutics inside the allocation mix. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.
Explore our How to Trade Cognition Stock guide to learn how to trade Cognition Therapeutics effectively.Analysis related to Cognition Therapeutics should be read together with other portfolio and risk tools before capital is reallocated. That is especially important when the goal is to improve the overall mix of instruments already held. You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.
Earnings Share
-0.47
Return On Assets
-0.79
Return On Equity
-1.10
Investors evaluate Cognition Therapeutics using market value and book value, each describing different facets of the business. Cognition Therapeutics' market capitalization is 98.87 M. A P/B ratio of 2.72 indicates the market values Cognition Therapeutics above its accounting book value. Enterprise value stands at 60.35 M. Intrinsic value is an estimate of what Cognition Therapeutics' fundamentals imply, and it may differ from market and book figures. Analytical frameworks help compare those viewpoints.
Value and price for Cognition Therapeutics are related but not identical, and they can diverge across cycles. For Cognition Therapeutics, key inputs include a P/B ratio of 2.72, and ROE of -109.73%. By contrast, market price reflects the level where buyers and sellers transact.
Raphi Shpitalnik ยท Junior Member of Macroaxis Editorial Board